Novo Nordisk A/S (NYSE:NVO) Trading 2.1% Higher

Novo Nordisk A/S (NYSE:NVO)’s stock price was up 2.1% during mid-day trading on Tuesday . The company traded as high as $127.42 and last traded at $127.23. Approximately 1,233,145 shares changed hands during trading, a decline of 74% from the average daily volume of 4,806,679 shares. The stock had previously closed at $124.59.

Analysts Set New Price Targets

NVO has been the subject of a number of analyst reports. UBS Group initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. Finally, BMO Capital Markets started coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Stock Up 2.2 %

The stock has a market capitalization of $571.22 billion, a price-to-earnings ratio of 43.87, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average of $127.22 and a two-hundred day moving average of $113.29.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Pacific Center for Financial Services increased its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the last quarter. First PREMIER Bank acquired a new position in Novo Nordisk A/S in the 1st quarter worth about $25,000. Bell Investment Advisors Inc increased its position in Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. CNB Bank acquired a new position in Novo Nordisk A/S in the 4th quarter worth about $26,000. Finally, Dixon Mitchell Investment Counsel Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter worth about $26,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.